{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:37:28Z","timestamp":1784831848689,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.clinbiochem.2017.10.008","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T16:18:58Z","timestamp":1508170738000},"page":"106-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Description of analytical method and clinical utility of measuring serum 7-alpha-hydroxy-4-cholesten-3-one (7aC4) by mass spectrometry"],"prefix":"10.1016","volume":"52","author":[{"given":"Leslie J.","family":"Donato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Lueke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy M.","family":"Kenyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Meeusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Camilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2017.10.008_bb0005","first-page":"71","article-title":"The epidemiology of irritable bowel syndrome","volume":"6","author":"Canavan","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.clinbiochem.2017.10.008_bb0010","article-title":"Bowel Disorders","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.clinbiochem.2017.10.008_bb0015","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.dld.2009.07.009","article-title":"Current and novel therapeutic options for irritable bowel syndrome management","volume":"41","author":"Camilleri","year":"2009","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.clinbiochem.2017.10.008_bb0020","doi-asserted-by":"crossref","DOI":"10.1007\/164_2016_102","article-title":"Irritable bowel syndrome: pathophysiology and current therapeutic approaches","author":"Camilleri","year":"2016","journal-title":"Handb. Exp. Pharmacol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2017.10.008_bb0025","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5009\/gnl14397","article-title":"Bile acid diarrhea: prevalence, pathogenesis, and therapy","volume":"9","author":"Camilleri","year":"2015","journal-title":"Gut Liver"},{"issue":"10","key":"10.1016\/j.clinbiochem.2017.10.008_bb0030","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.cgh.2013.04.020","article-title":"Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome","volume":"11","author":"Shin","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2017.10.008_bb0035","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1517\/13543784.2015.1025132","article-title":"Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials","volume":"24","author":"Valentin","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"5","key":"10.1016\/j.clinbiochem.2017.10.008_bb0040","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1053\/j.gastro.2010.07.052","article-title":"Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis","volume":"139","author":"Rao","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinbiochem.2017.10.008_bb0045","article-title":"Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis","author":"Valentin","year":"2015","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.clinbiochem.2017.10.008_bb0050","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/apt.13065","article-title":"Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome","volume":"41","author":"Camilleri","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.clinbiochem.2017.10.008_bb0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gutjnl-2013-305965","article-title":"Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS","volume":"64","author":"Bajor","year":"2015","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.clinbiochem.2017.10.008_bb0060","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cgh.2012.05.006","article-title":"Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea","volume":"10","author":"Wong","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2017.10.008_bb0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00042737-199602000-00005","article-title":"Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea","volume":"8","author":"Brydon","year":"1996","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2017.10.008_bb0070","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1053\/j.gastro.2005.09.009","article-title":"Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis","volume":"129","author":"Galman","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.clinbiochem.2017.10.008_bb0075","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.clinbiochem.2017.10.008_bb0080","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJMra1207068","article-title":"Peripheral mechanisms in irritable bowel syndrome","volume":"367","author":"Camilleri","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.clinbiochem.2017.10.008_bb0085","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/ajg.2011.162","article-title":"A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation","volume":"106","author":"Chey","year":"2011","journal-title":"Am. J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2017.10.008_bb0090","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/ajg.2011.285","article-title":"Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation","volume":"106","author":"Wong","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clinbiochem.2017.10.008_bb0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchromb.2016.08.046","article-title":"Comparison of simple extraction procedures in liquid chromatography-mass spectrometry based determination of serum 7alpha-hydroxy-4-cholesten-3-one, a surrogate marker of bile acid synthesis","volume":"1033-1034","author":"Lenicek","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"7","key":"10.1016\/j.clinbiochem.2017.10.008_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2982.2009.01288.x","article-title":"Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry","volume":"21","author":"Camilleri","year":"2009","journal-title":"Neurogastroenterol. Motil."},{"issue":"1","key":"10.1016\/j.clinbiochem.2017.10.008_bb0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1023\/A:1026681512303","article-title":"Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum","volume":"44","author":"Sauter","year":"1999","journal-title":"Dig. Dis. Sci."},{"issue":"9","key":"10.1016\/j.clinbiochem.2017.10.008_bb0110","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cgh.2015.03.002","article-title":"High prevalence of idiopathic bile acid diarrhea among patients with diarrhea-predominant irritable bowel syndrome based on Rome III criteria","volume":"13","author":"Aziz","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.clinbiochem.2017.10.008_bb0115","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2036.2009.04081.x","article-title":"Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome","volume":"30","author":"Wedlake","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.clinbiochem.2017.10.008_bb0120","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/apt.14214","article-title":"Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea","volume":"46","author":"Vijayvargiya","year":"2017","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912017307427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912017307427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:51:07Z","timestamp":1757865067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912017307427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":24,"alternative-id":["S0009912017307427"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2017.10.008","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Description of analytical method and clinical utility of measuring serum 7-alpha-hydroxy-4-cholesten-3-one (7aC4) by mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2017.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}